key: cord-0896474-ign5kwh7 authors: Yang, Yang; Gong, Xiaohua; Yang, Liuqing; Li, Jie; Zhang, Jiaqi; Wei, Lanlan; Ye, Guoguo; Tang, Yimin; Jiang, Yujing; Li, Jianhuan; Lin, Yuanlong; Wang, Fuxiang; Lu, Hongzhou; Liu, Yingxia title: Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees date: 2022-01-10 journal: J Infect DOI: 10.1016/j.jinf.2022.01.004 sha: c535c93f8f7d048116819a76e5b597423b106226 doc_id: 896474 cord_uid: ign5kwh7 nan . Significantly higher ID 50 against both Delta (3.25-fold) and Omicron variants (1.77-fold) were also found in the breakthrough infections (Figure 1D) . For the Beta group, we only got the naive infections, and reduced neutralizing activities were also found with 18.38-fold reduction against the Omicron variant ( Figure 1C) . In the Vaccinee group, 91.66 (22/24) showed detectable ID 50 against wild type SARS-CoV-2 at 95 days post booster vaccination with GMT of 299, and 1.67-fold, 14.52-fold, 6.73-fold and 3.72-fold reduction against Alpha, Beta, Gamma and Delta variants were found, respectively (Figure 2A) . Notably, only 25% (6/24) of the samples showed detectable ID 50 against Omicron, with 16.07-fold reduction when compared with wild type SARS-CoV-2. We further compared the neutralization activity before and after booster vaccination against different VOCs. After booster vaccination, GMTs of ID 50 against wild type, Alpha, Beta, Gamma, Delta increased 13.47-fold, 8.63-fold, 2.06-fold, 6.75-fold and 3.96 fold, respectively ( Figure 2B) . The authors have declared that no conflicts of interest exist. The biological and clinical significance of emerging SARS-CoV-2 variants Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations Maturation and persistence of the anti-SARS-CoV-2 memory B cell response Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection